Virax Biolabs Group Limited (VRAX) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is bullish — 1 Buy.
The consensus price target is $1.00, representing an upside of 567.6% from the current price $0.15.
Analysts estimate Earnings Per Share (EPS) of $-1.90 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.36 vs est $-1.90 (missed -76.8%). 2025: actual $-1.96 vs est $-1.48 (missed -32.4%). Analyst accuracy: 66%.
VRAX Stock — 12-Month Price Forecast
$1.00
▲ +567.56% Upside
Average Price Target
Based on 1 Wall Street analysts offering 12-month price targets for Virax Biolabs Group Limited, the price target is $1.00.
The average price target represents a +567.56% change from the last price of $0.15.
VRAX Analyst Ratings
Buy
Based on 1 analysts giving stock ratings to Virax Biolabs Group Limited in the past 3 months
EPS Estimates — VRAX
66%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$3.36
vs Est –$1.90
▼ 43.5% off
2025
Actual –$1.96
vs Est –$1.48
▼ 24.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — VRAX
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.000B
vs Est $0.001B
▼ 795.0% off
2025
Actual $0.000B
vs Est $0.000B
▼ 294.9% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
